PDCD1 and neoplasm: A bispecific anti-PD-1 and TIM-3 antibody (RO7121661/RG7769) demonstrated superior antitumor TIL activity, IFN-γ secretion, and tumor growth control compared to the monospecific PD-1 antibody in mouse models [134].